REGENXBIO Inc. (RGNX)
| Market Cap | 730.77M +64.0% |
| Revenue (ttm) | 174.48M +12.0% |
| Net Income | -196.43M |
| EPS | -3.77 |
| Shares Out | 66.01M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 623,919 |
| Open | 11.13 |
| Previous Close | 11.33 |
| Day's Range | 10.73 - 11.20 |
| 52-Week Range | 5.46 - 16.19 |
| Beta | 0.94 |
| Analysts | Buy |
| Price Target | 24.55 (+121.77%) |
| Earnings Date | Aug 6, 2026 |
About RGNX
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-12... [Read more]
Financial Performance
In 2025, REGENXBIO's revenue was $170.44 million, an increase of 104.54% compared to the previous year's $83.33 million. Losses were -$193.88 million, -14.63% less than in 2024.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for RGNX stock is "Buy." The 12-month stock price target is $24.55, which is an increase of 121.77% from the latest price.
News
Regenxbio price target lowered to $23 from $26 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Regenxbio (RGNX) to $23 from $26 and keeps a Buy rating on the shares post the Q2 report. The firm cites the…
Regenxbio price target raised to $18 from $16 at Morgan Stanley
Morgan Stanley analyst Judah Frommer raised the firm’s price target on Regenxbio (RGNX) to $18 from $16 and keeps an Overweight rating on the shares.
Regenxbio downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Eliana Merle downgraded Regenxbio (RGNX) to Equal Weight from Overweight with an unchanged price target of $12. The firm sees potential upside for the company’s wholly-owned RGX-202 f...
REGENXBIO Earnings Call Transcript: Q2 2026
Key milestones achieved in late-stage gene therapy programs, including full enrollment in pivotal studies and FDA alignment for accelerated approval. Financial position strengthened with over $310 million pro forma cash, supporting a runway into Q4 2027 and multiple upcoming regulatory and commercial milestones.
REGENXBIO Earnings release: Q2 2026
REGENXBIO released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
REGENXBIO Quarterly report: Q2 2026
REGENXBIO has published its Q2 2026 quarterly earnings report on August 6, 2026.
Regenxbio reports Q2 EPS 43c vs. ($1.38) last year
Reports Q2 revenue $108M, consensus $96.46M. “Our second quarter was defined by strong clinical execution across our pipeline: the Phase III AFFINITY DUCHENNE trial met its primary endpoint, we dosed…
REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027 Long-term surabgene lomparvovec (sura-vec, ABBV-RGX-314) data hig...
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights
ROCKVILLE, Md., Aug. 3, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Thursday, August 6, at 8:00 a.m.
Regenxbio presents long-term data for surabgene lomparvovec
Regenxbio (RGNX) announced positive data from long-term follow-up studies of investigational surabgene lomparvovec in wet AMD using subretinal delivery and diabetic retinopathy, DR, using suprachoroid...
REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting
One-time gene therapy treatment with sura-vec demonstrated long-term efficacy at similar doses to those being evaluated in ongoing late-stage studies: Stable to improved vision through 5 years in wet ...
Regenxbio 10M share Spot Secondary priced at $9.00
Regenxbio (RGNX) announced the pricing of an underwritten public offering of 10,003,889 shares of its common stock at the price of $9.00 per share and 1,111,111 pre-funded warrants at a…
REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants
ROCKVILLE, Md., July 17, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the pricing of an underwritten public offering of 10,003,889 shares of its common stock at the price of $9.0...
Regenxbio announces $100M common stock offering
Regenxbio (RGNX) announced that it intends to offer and sell, subject to market conditions, $100M of its common stock in an underwritten public offering. Morgan Stanley, J.P. Morgan, Leerink Partners…
REGENXBIO Announces Proposed Public Offering of Common Stock
ROCKVILLE, Md., July 16, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it intends to offer and sell, subject to market conditions, $100 million of its common stock in an unde...
Regenxbio says first patient dosed in Phase IIb/III NAAVIGATE trial
Regenxbio (RGNX) announced the first patient has been dosed in the Phase IIb/III NAAVIGATE clinical trial of investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) in diabetic retinopathy usin...
REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone
New long-term data from diabetic retinopathy and wet AMD programs to be presented at American Society of Retina Specialists (ASRS) 2026 ROCKVILLE, Md., June 29, 2026 /PRNewswire/ -- REGENXBIO Inc. (Na...
Regenxbio completes dosing in confirmatory study of RGX-202
Regenxbio (RGNX) announced the successful completion of dosing in the confirmatory study of RGX-202, a potential best-in-class gene therapy for Duchenne muscular dystrophy. This milestone positions Re...
REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026
Confirmatory study completed ahead of schedule due to strong patient demand and robust investigator interest On track to initiate BLA in Q3 2026 under the accelerated approval pathway supporting poten...
Regenxbio price target raised to $32 from $27 at Baird
Baird raised the firm’s price target on Regenxbio (RGNX) to $32 from $27 and keeps an Outperform rating on the shares. The firm updated its model the reflect the FDA-aligned…
H.C. Wainwright notes Regenxbio doesn’t need more studies for BLA resubmission
After Regenxbio (RGNX) announced that it has aligned with the FDA regarding the resubmission of the Biologics License Application for Navsunli for Mucopolysaccharidosis II or Hunter syndrome, H.C. Wai...
Regenxbio aligns with FDA on path forward for Navsunli
Regenxbio (RGNX) announced it has aligned with the U.S. FDA regarding the next steps needed for a potential accelerated approval of Navsunli, the only potential one-time treatment and gene therapy…
REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II
FDA confirmed no additional studies required, existing longer-term data from the CAMPSIITE ® study will be reviewed on an expedited basis for approval via the accelerated approval pathway The Company ...
FDA to reverse rejection of Regenxbio's rare-disease drug, WSJ reports
The U.S. Food and Drug Administration will reverse its earlier rejection of a rare-disease therapy from Regenxbio , the Wall Street Journal reported on Monday.
Regenxbio up 25% after saying FDA will reverse rejection, consider application
Regenxbio (RGNX) shares are up $1.97, or 25% to $9.77 in pre-market trading after after Chief Executive Curran Simpson said the Food and Drug Administration has agreed to reverse its…